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Abstract: Pompe disease, or glycogen storage disease II is a rare, progressive disease leading to 
skeletal muscle weakness due to deficiency of the acid α-1,4-glucosidase enzyme (GAA). The 
severity of disease and observed time of onset is subject to the various combinations of heterozygous 
GAA alleles. Here we have characterized two novel mutations: c.2074C>T and c.1910_1918del, and 
a previously reported c.1082C>G mutation of uncertain clinical significance. These mutations were 
found in three unrelated patients with adult-onset Pompe disease carrying the common c.-32-13T>G 
mutation. The c.2074 C>T nonsense mutation has obvious consequences on GAA expression but the 
c.1910_1918del (deletion of 3 amino acids) and c.1082C>G missense variants are more subtle DNA 
changes with catastrophic consequences on GAA activity. Molecular and clinical analyses from the 
three patients corresponded with the anticipated pathogenicity of each mutation. 
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1. Introduction 
Pompe disease, also known as glycogen storage disease type II (GSD II) (OMIM #232300) [1,2], 
is caused by mutations in the GAA located on chromosome 17q25.2–q25.3 [3]. GSD II prevalence is 
estimated to be 1 in 5,000 to 10,000 births, depending on the ethnicity and geographic regions, and is 
inherited in an autosomal recessive manner [4]. The GAA encodes the acid α-1,4-glucosidase enzyme 
(GAA) (EC 3.2.1.3) that breaks down glycogen within the lysosomes. Therefore, a deficiency of GAA 
activity will result in the accumulation of glycogen in the cell, particularly affecting cellular functions 
in cardiac and skeletal muscles [5].  
Depending upon the levels of residual GAA activity, presentation of Pompe disease may vary 
from the severe form with infantile-onset to a much slower but still progressive juvenile or adult-
onset form [6]. The levels of residual GAA enzyme activity present in Pompe patients appears to be 
the primary determinant for the age onset, the tissues involved (cardiac or not) and the severity of 
the disease [7–9]. In general, less than 1% of GAA activity is found in Pompe patients with severe 
infantile-onset, whereas some juvenile and most late-onset patients [6] have enzyme levels varying 
between 2–40% activity. The variation in the residual GAA activity is generally a consequence of 
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various combinations of heterozygous GAA alleles that range from null mutations to those with 
partial activity [10].  
More than 500 different mutations have been identified in the GAA gene to date, and include 
missense, nonsense, splicing defects, as well as frame-shifting deletions (1 to ~3000 nucleotides), 
duplications (1 to 17 nucleotides) and gross chromosomal rearrangements (www.pompecenter.nl). 
One-third of the variants confirmed to be pathogenic show consistent severe phenotype if found in 
conjunction with another severe mutation. While many nonsense and frame-shifting indels are 
consistent with a null allele and loss of a functional transcript, some missense variants/mutations also 
impair function and may partially compromise enzyme activity. 
In this paper, we characterized two novel mutations, c.2074C>T, c.1910_1918del, and a 
previously reported c.1082C>G variant of uncertain clinical significance found in unrelated late-onset 
Pompe disease patients, also carrying the common c.-32-13T>G GAA variant. Since residual GAA 
activity in the adult-onset condition is presumed to arise solely from incomplete mis-splicing of exon 
2 from the allele carrying the c.-32-13T>G mutation, the three novel mutations are predicted to abolish 
GAA function and would be associated with the severe phenotype if inherited with another null 
allele. Analysis of both GAA transcript and protein from all three patients correlates with the 
observed phenotypes.  
2. Materials and Methods  
2.1. Ethics Approvals  
The use of human cells was approved by Murdoch University Human Research Ethics 
Committee (approval 2013/156) and the Western Sydney Local Health District (WSLHD) Human 
Research Ethic Committee, Australia (approval HREC/17/WMEAD/358). Patient biopsies were 
collected after informed consent at the Westmead Hospital. Samples were prepared and analyzed in 
accordance with the protocols approved by the ethics committees of Murdoch University and 
WSLHD. 
2.2. Cell Culture  
All cell culture reagents were purchased from Thermo Fisher Scientific Australia Pty. Ltd. 
(Scoresby, Australia) and cultures were maintained at 37 °C under a 5% CO2/95% air atmosphere 
unless otherwise stated. Human dermal fibroblasts were propagated in DMEM supplemented with 
L-glutamine and 10% foetal bovine serum. 
2.3. Genomic DNA and RNA Extraction  
Genomic DNA was extracted using PureLink® Genomic DNA mini kit (Thermo Fisher Scientific, 
Scoresby, Australia) according to the manufacturer’s instructions. Total RNA was extracted using 
MagMax™ nucleic acid isolation kit (Thermo Fisher Scientific, Scoresby, Australia) according to the 
manufacturer’s instructions incorporating the DNase step included in the kit. Total RNA was 
assessed using the Nanodrop (ND-1000, Thermo Fisher Scientific, Scoresby, Australia) for quality 
and quantity. cDNA was synthesised using 125 ng of total RNA, 200 ng of random hexamers (Thermo 
Fisher Scientific, Scoresby, Australia) and SuperScript® IV reverse transcriptase (Thermo Fisher 
Scientific, Scoresby, Australia) in 20 µL reactions. 
2.4. PCR, RT-PCR and qPCR 
DNA (20 ng) or cDNA (0.5 µL) was amplified using TaKaRa LA Taq DNA polymerase with GC 
buffer II (Takara Bio USA, Inc., Clayton, Australia), the primers and conditions listed in Table 1. The 
PCR products were fractionated on 2% agarose gels in Tris-acetate EDTA buffer and images were 
captured using a Fusion-FX gel documentation system (Vilber Lourmat, Eberhardzell, France). 
Sequencing was performed at the Australian Genome Research Facility (Perth, Australia) and 
compared to the reference GAA genomic sequence (Accession: NG_009822.1) using BLAST [11]. The 
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qPCR reactions were prepared using fast SYBR™ Green (Thermo Fisher Scientific, Scoresby, 
Australia), 100 nM (96.5% primer efficiency) and 500 nM (104.9% primer efficiency) primers for GAA 
and TBP transcript, respectively and a CFX384 Touch™ Real-Time PCR detection system (Bio-Rad 
Laboratories Pty., Ltd., Gladesville, Australia). GAA (Accession: NM_000152.4) transcript expression 
relative to the reference transcript TBP (Accession: NM_003194.4) was calculated. The expression of 
the GAA transcript relative to TBP mRNA was analyzed using the Bio-Rad CFX Manager™ Software 
Version 3.1 (Bio-Rad Laboratories Pty., Ltd., Gladesville, Australia) and the 2-ΔΔCT method and 
presented as a fold change compared to healthy control fibroblasts. 
2.5. Western Blotting 
Western blotting was performed on 10 µg of total protein, as determined by Pierce™ BCA 
protein assay kit (Thermo Fisher Scientific, Scoresby, Australia), fractionated on NuPAGE Novex 4–
12% BIS/Tris gels (Thermo Fisher Scientific, Scoresby, Australia) and transferred to Pall FluoroTrans® 
membranes (Fisher Biotec, Wembley, Australia). The membrane was probed using the antibodies 
listed in Table 2 for overnight at 4 °C and detected using Luminata Crescendo Western HRP substrate 
(Merck Millipore, Bayswater, Australia) and Fusion FX system (Vilber Lourmat, Eberhardzell, 
France). 
2.6. GAA Enzyme Activity Assay 
GAA enzyme activity of dried blood spots was determined using the substrate 4-
methylumbelliferyl-α-D-glucopyranoside at the National Referral Laboratory (Adelaide, Australia). 
To test the activity in cells derived from patients and healthy volunteers, cell pellets were collected 
by trypsinisation and centrifugation and stored at −80 °C until the assays were performed. The pellets 
were subjected to three freeze-thaw cycles before resuspension in 50 µL of lysis buffer [10 mM 
HEPES, 70 mM sucrose, 220 mM mannitol supplemented with 1 x protease inhibitors] and sonicated 
6 times for 1 s. The cell lysate was centrifuged at 12,000 ×g for 10 min at 4 °C, the supernatant was 
collected, and total protein concentration was measured using Pierce™ BCA protein assay kit 
(Thermo Fisher Scientific, Scoresby, Australia). Approximately 3–5 µg of the total protein lysate in 10 
µL volume was used for enzymatic reactions under two pH conditions, 3.9 (for acid-α-glucosidase 
activity) and 6.5 (for neutral α-glucosidase activity). GAA enzyme activity was initiated by adding 
20 µL of 1.4 mM artificial substrate 4-methylumbelliferyl-β-D-glucopyranoside (4-MUG) prepared in 
two 0.2 M acetate buffers, pH 3.9 and pH 6.5. The reaction was incubated for 1 h at 37 °C before 
adding 200 µL of stop buffer (0.5 M sodium carbonate, pH 10.7). The fluorescent signals were 
measured using FLUOstar Omega (BMG LABTECH, Mornington, Australia) with 355 nm excitation 
and 460 nm emission filters. The ratio of signals generated at pH 3.9 to those at pH 6.5 was calculated. 
All assays were performed in triplicates. 
2.7. Measurement of Urinary Tetrasaccharide 
Urinary tetrasaccharide levels, normalised to creatinine, were determined by tandem mass 
spectrometry at the National Referral Laboratory (Adelaide, Australia). 
2.8. In Silico Predictions 
Pathogenicity of the mutations identified in patients was predicted using Mutation Taster 
(http://mutationtaster.org) [12]. GAA gene was used as an input, and transcript ID ENST00000302262 
was chosen for all analysis. The results were also compared to the mutations found for the same 
amino acid reported by others.  
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Table 1. Primers and antibodies used in this study. 
Primer names Sequences (5´ to 3´) Purpose Cycling 
conditions 
PCR 
intron 1F  




























Genomic DNA amplification 
data 
95 °C for 5 
min, 35 cycles 
of 95 °C 30 s, 
60 °C 30 s and 























GAA transcript amplification 
95 °C for 5 min 
35 cycles of 95 
°C 30 s, 60 °C 


















Full-length GAA transcript 
(exon 1-2), amplification 
 
TBP transcript amplification 
95 °C for 1 
min, 40 cycles 
of 95 °C 3 s, 60 
°C 15 s and 72 
°C 30 s 
    
Antibodies Catalogue no. Source Dilution 










Sigma-Aldrich, Castle Hill 
NSW 
1: 500,000  
3. Results 
3.1. Clinical Assessment  
Patient 1, a Caucasian with non-consanguineous parents, has a history of progressive weakness 
of the limbs for more than 10 years since presentation. Although this patient remains independently 
ambulant at age 54 years, a muscle biopsy showed vacuoles of glycogen. Respiratory symptoms 
improved significantly on nocturnal bi-level ventilation. Patient 2 is of Syrian ancestry with non-
consanguineous parents and an 8-year history of progressive limb-girdle weakness. A muscle biopsy 
showed sub-sarcolemmal glycogen vacuoles. Patient 9 is Caucasian with non-consanguineous 
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parents and had been first examined at age 16. Hip girdle strength was subtly decreased. Shown in 
Table 2 is a summary of patient details and clinical assessment. 



















Patient 1 54 320 
Type 2 respiratory 
failure 
(pCO2 55 mmHg) 
<0.1 61 
Patient 2 44  Intact <0.2 150 
Patient 9 30 950 Intact 0.8 40 
3.2. Molecular Analysis 
We established patient and healthy-derived fibroblast cell strains from skin biopsies, propagated 
as outlined in the materials and methods section, and performed molecular analyses. Since all three 
Pompe patients were adult-onset, we suspected that these patients might be carrying the common 
GAA mutation, c.-32-13T>G, found in more than two-thirds of adult-onset cases. Cryptic splicing 
products are characteristic of the c.-32-13T>G mutation [6,7] and was assessed by RT-PCR 
amplification across GAA exons 1 to 5 (Figure 1A) from total RNA extracted from cultured fibroblasts. 
Cryptic splicing products were observed in all three patients but not in the two healthy samples. We 
also amplified the remainder of the GAA transcript, exons 6 to 20, from all three patients and 
compared these to those from healthy fibroblasts (Figure 1A) to assess the impact of the second 
mutations on the GAA transcript processing. The amplicons representing the GAA transcripts from 
patient 1 and 2 were consistently less abundant than those generated from the other patients and 
healthy controls. Apart from this observation, there were no noticeable changes in the sizes of GAA 
transcript amplicons derived from all patients.  
The sequencing of genomic DNA amplicons confirmed the presence of c.-32-13T>G in all 
patients (Figure 1B). The c.1910_1918del (p.Leu637_Val639del) and c.1082C>G (p.Pro361Arg) 
mutations were identified from the RT-PCR amplicons from patients 2 and 9, respectively. However, 
no second mutation was found for patient 1, despite complete sequencing of the overlapping RT-PCR 
products spanning the GAA transcript. The absence of other abnormal GAA transcript amplicons and 
the consistently low levels of the GAA amplicons in patient 1 (Figure 1A), led us to speculate that the 
second mutation could be inducing robust nonsense-mediated decay (NMD) of that transcript. 
Amplification and sequencing of individual GAA exons and flanking intronic sequences from patient 
1 genomic DNA, using the primers shown in Table 1, revealed a c.2074C>T (p.Gln692X) mutation in 
exon 15.  
In addition to identifying mutations in all three patients, we also estimated the levels of full-
length GAA transcript containing exon 2 by RT-qPCR analysis in all patients and compared these to 
that observed in the two healthy controls (Figure 1C). Substantial variation in GAA transcript levels 
was evident between the two healthy controls, with healthy control 2 expressing 30% lower levels 
than that seen in healthy control 1. Patient 1 expressed the lowest amount of full-length GAA 
transcript among all patients, approximately half of the levels of healthy control 2. Since the second 
GAA allele carrying c.2074C>T (p.Gln692X) is subjected to NMD in patient 1, the full-length product 
detected for this patient is mainly contributed by the transcripts that escaped cryptic splicing, caused 
by the c.-32-13T>G mutation.  
The amount of full-length GAA transcript expressed in patient 2 is similar to that from healthy 
control 2, while patient 9 had higher levels than those observed in healthy control 1. The full-length 
GAA transcript products amplified for both patients 2 and 9 are transcribed from both alleles, 
although the majority are contributed by the allele carrying the c.1910_1918del (p.Leu637_Val639del) 
mutation in patient 2 and c.1082C>G (p.Pro361Arg) in patient 9.  
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Both RT-PCR and RT-qPCR analysis showed that there were substantial variations in the level 
of GAA transcript in all three patients. Therefore, we performed enzyme activity assays using protein 
extracts derived from the patients to determine the residual activities in these patients and correlated 
to the GAA transcript levels (Figure 1D). Protein extracts from healthy control fibroblasts were also 
included as controls. The GAA activity differed significantly between the healthy individuals, with 
healthy control 1 having twice the activity of healthy control 2. As anticipated, protein extracts from 
the patient cultured cells had less than 30% of the activity of healthy control 2. Interestingly, although 
all three patients expressed different levels of full-length GAA transcript, as detected by RT-qPCR, 
similar levels of GAA enzyme activity were observed for all patients. This result indicated that the 
higher levels of full-length GAA transcript observed in patients 2 and 9 compared to patient 1, arising 
from the GAA allele with the c.1910_1918del (p.Leu637_Val639del) and c.1082C>G (p.Pro361Arg) 
mutations respectively, did not produce a considerable amount of functional protein.  
To determine whether the observed low GAA activity, despite high levels of GAA transcript, in 
patient 2 and 9 was due to defective production of GAA protein, we analyzed the levels of GAA 
protein expressed in all patients and control fibroblasts (Figure 1E). We prefer utilising patient-
derived fibroblasts over the conventional method of artificially overexpressing mutated protein, as 
artificially overexpressing mutant protein can introduce confounding factors. Both healthy controls 
expressed similar quantities of active (70 and 76 kD) and intermediate (95 kD) GAA proteins, and 
limited levels of precursor protein (110 kD). A protein band migrating slower than 110 kD was also 
observed in all samples. All three patients’ fibroblasts expressed approximately 50% of the amount 
of mature active GAA proteins (70 and 76 kD) detected in healthy control 2. In patients 2 and 9, there 
were low levels of precursor protein (110 kD), which was absent in patient 1. These results, together 
with the transcript analysis, indicates that the active GAA proteins (70 and 76 kD) found in patient 2 
and 9 were translated from the GAA transcript that escaped cryptic splicing from to the c.-32-13T>G 
mutation allele, and the 110 kD precursor protein was translated from the second allele unable to 
undergo maturation.  
3.3. In Silico Analysis 
The mutations identified in this study were subjected to in silico analysis using Mutation Taster 
[12]. The gene and transcript ID, GAA and ENST00000302262, respectively and the coding sequence 
positions were selected for the analysis. The outputs of Mutation Taster include DNA and amino acid 
changes, report of known variants, possible splice site changes, alignment of amino acids to 
determine conservation and protein features, such as glycosylation. 
Not all nonsense mutations may induce efficient NMD, however we confirmed that this was the 
case for patient 1 during molecular analysis with RT-PCR and DNA sequencing failing to detect this 
allele. The c.2074C>T (p.Gln692X) GAA variant should be pathogenic as the amino acid Gln692 is 
replaced by a stop codon and the resulting protein will be missing the C terminal 783 amino acids. 
One predicted consequence of this mutation was induction of abnormal splicing of exon 15 due to 
possible activation of a donor splice site, with the score increasing from 0.79 to 0.94 at gDNA position 
11692.  
The nine base deletion, c.1910_1918del (p.Leu637_Val639del) found in patient 2 would cause an 
in-frame loss of three amino acids encoded within exon 14, potentially affecting protein feature or 
possible gain of an acceptor site. Two other pathogenic mutations have been reported for the amino 
acid Gly638 (substitutions of Val638 or Trp638). All three amino acids deleted, Leu637, Gly638 and 
Val639, are conserved in murine and chimpanzee GAA protein and since no abnormal splicing was 
detected, it would appear that the loss of these 3 amino acids seriously compromises GAA activity. 
Although the software predicted possible activation of a cryptic acceptor site, we did not detect any 
abnormal splicing in patient 2 mRNA. It was of interest to note that Mutation Taster predicted this 
was a polymorphism rather than pathogenic variant. 
However, the missense change of c.1082C>G (p.Pro361Arg) observed in patient 9 was analyzed 
using Mutation Taster and predicted to be a disease-causing mutation. The program indicated 
possible effects on protein features, and substitutions of Pro361 with Leu361 that resulted in severe 
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juvenile-onset Pompe have been reported. This amino acid is conserved in both mouse and 
chimpanzee and is part of the glycosyl hydrolases family 31. Abnormal GAA pre-mRNA splicing was 
not predicted since the changes in the splice site score were minimal.  
 
Figure 1. (A) RT-PCR analysis of GAA transcripts from fibroblasts derived from three Pompe patients 
and two healthy controls. (B) The mutations were identified and confirmed using Sanger sequencing 
for the three patients. The c.-32-13T>G and c.2074C>T mutations were identified from genomic DNA 
and the c.1910_1918del and c.1082C>G from RT-PCR products. (C) RT-qPCR analysis of the full-
length GAA transcript containing exon 2. (D) GAA activity (N = 3, Error bar = SD) and (E) western 
blotting analysis of GAA (110, 95, 75 and 70 kD) from fibroblasts derived from three patients and two 
healthy controls. 
4. Discussion 
We report three pathogenic mutations c.2074C>T (p.Gln692X), c.1910_1918del 
(p.Leu637_Val639del) and c.1082C>G (p.Pro361Arg) found in adult-onset Pompe patients carrying 
the common GAA mutation c.-32-13T>G. Deficiency in GAA activity was confirmed in both dried 
blood spot analyses and in vitro assays using protein extracts from dermal fibroblasts derived from 
patients and healthy individuals. Surprisingly, GAA enzyme activity was found to vary two-fold in 
the dermal fibroblasts between two healthy controls, although the lower level observed in healthy 
control 2 was still several fold higher than that found in the three patient derived dermal fibroblasts.  
It has been reported that some 25% of pathogenic missense and nonsense mutations disrupt 
normal pre-mRNA splicing [13] and consequently RT-PCR studies on the GAA mRNA are necessary 
to fully characterise these mutations. Apart from the c.-32-13T>G variant promoting GAA exon 2 
skipping, none of the other mutations reported here generate abnormally processed GAA transcripts. 
The c.2074C>T (p.Gln692X) gene lesion is an obvious pathogenic null allele and was not initially 
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detected during the mRNA screen, as this mutation induced robust NMD of the GAA transcript 
variant. Nonsense-mediated decay inhibitor can stabilise a transcript with a nonsense mutation and 
increase detection of the nonsense mutation [14]. Consequently, any GAA protein observed in patient 
1 must have been translated solely from the normal GAA mRNA transcripts that escape the abnormal 
splicing of exon 2 caused by the c.-32-13T>G mutation.  
Frequently, the effect of mutations on protein production, maturation and activity are studied 
using an in vitro system overexpressing the mutant protein. One significant limitation of this system 
is that overexpression of defective protein may lead to accumulation of misfolded aggregates in the 
endoplasmic reticulum. Therefore, we prefer to utilise patient-derived cells to study protein activity 
and expression. Based on our western blotting and GAA activity observations, the in-frame deletion 
of the c.1910_1918del (p.Leu637_Val639del) is unlikely to produce any functional GAA protein. 
Similarly, missense mutations of the highly conserved Gly638 have been reported as pathogenic by 
others [15–18], with low levels of GAA protein and less than 2% of normal GAA activity in patients 
with the infantile phenotype, in combination with a null mutation.  
The mutation carried by patient 9 (c.1082C>G, p.Pro361Arg) had been reported by EGL Genetic 
Diagnostics (Eurofins Clinical Diagnostics, Tucker, GA, USA) (rs755253527), although clinical 
significance was not provided. A different missense change involving the same amino acid 
(c.1082C>T, p.Pro361Leu) [19] was reported as pathogenic but postulated to retain some GAA 
activity. Protein and expression analysis in COS-7 or HEK293T cells, transiently transfected with 
mutated GAA cDNA, showed that the c.1082C>T mutation resulted in lower GAA protein levels [19]. 
These observations are consistent with the low level of GAA protein observed in cells derived from 
patient 9. 
In summary, we describe three different mutations that severely compromise GAA activity and 
propose that both c.1910_1918del (p.Leu637_Val639del) and c.1082C>G (p.Pro361Arg) mutations 
affect both activity and levels of GAA protein, either through inappropriate folding, stability and/or 
maturation. In addition, we encourage analyses of the consequences of mutation at the molecular 
level in addition to in silico analysis. These analyses can be performed using patient-derived cells such 
as dermal fibroblasts and myoblasts obtained from skin or muscle biopsies, respectively, or 
lymphocytes from blood samples.  
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